Q-omics provides the consensus-scored PLPP1 profile across patient tissues and cancer cell-line models. PLPP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLPP1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PLPP1 RNA expression shows 19,587 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where PLPP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLPP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLPP1 survival associations across molecular data types. PLPP1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLPP1 RNA expression–survival associations across cancer types. High PLPP1 expression shows unfavorable associations in ACC, KIRP and LGG, but favorable associations in KIRC, LIHC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLPP1 RNA expression.
This table summarizes PLPP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PLPP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLPP1 shows lower tumor expression in COAD, KICH, KIRP and LUAD and higher tumor expression in KIRC and LIHC. The COAD box plot shows higher PLPP1 RNA expression in normal versus tumor tissue (log2 FC = −1.768, t-test p < 0.001).
This table shows molecular features associated with PLPP1 in patient tissues and cancer cell lines. In patient samples, PLPP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLPP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
